+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Role of advanced glycation end products (AGE) and soluble receptor for AGE (sRAGE) in vascular complications in diabetes



Role of advanced glycation end products (AGE) and soluble receptor for AGE (sRAGE) in vascular complications in diabetes



Nihon Rinsho. Japanese Journal of Clinical Medicine 70(Suppl. 5): 243-247




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055600550

Download citation: RISBibTeXText

PMID: 23156401


Related references

Soluble form of receptor for advanced glycation end-products (sRAGE): do sRAGE ligands or anti-sRAGE auto-antibodies interfere with sRAGE quantification?. Annals of Clinical Biochemistry 51(Pt 2): 248-257, 2014

Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Current Drug Targets 8(10): 1138-1143, 2007

Advanced glycation end products (AGEs) and the soluble receptor for AGE (sRAGE) in patients with type 1 diabetes and coeliac disease. Nutrition, Metabolism, and Cardiovascular Diseases 25(2): 230-235, 2015

Reduced soluble receptor for advanced glycation end-products (sRAGE) scavenger capacity precedes pre-eclampsia in Type 1 diabetes. Bjog 119(12): 1512-1520, 2012

Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Molecular Medicine 13(3-4): 185-189, 2007

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology 27(6): E32; Author Reply E33-4, 2007

Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvascular Research 76(1): 52-56, 2008

The Relationship of Serum Soluble Receptor for Advanced Glycation End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic Nephropathy in Persons With Type 1 Diabetes. Diabetes Care 40(9): E117-E119, 2017

Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients. Mediators of Inflammation 2018: 1347432, 2018

Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 59(8): 2027-2032, 2010

The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrology, Dialysis, Transplantation 11(Suppl. 5): 13-16, 1996

Solution structure of the soluble receptor for advanced glycation end products (sRAGE). Journal of Biological Chemistry 286(43): 37525-37534, 2011

Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Frontiers in Bioscience 2: 1184-1195, 2010

Critical Appraisal of Advanced Glycation End Products (AGEs) and Circulating Soluble Receptors for Advanced Glycation End Products (sRAGE) as a Predictive Biomarkers for Cardiovascular Disease in Hemodialysis Patients. Medical Sciences 6(2), 2018

Generation of Soluble Advanced Glycation End Products Receptor (sRAGE)-Binding Ligands during Extensive Heat Treatment of Whey Protein/Lactose Mixtures Is Dependent on Glycation and Aggregation. Journal of Agricultural and Food Chemistry 64(33): 6477-6486, 2017